gtag('event', 'click', { 'event_category': 'PDF Download' });
was successfully added to your cart.



NICE confirms Odevixibat as treatment for PFIC

We are delighted to see that today NICE has confirmed that Odevixibat (Bylvay) will now be available on the NHS as a possible treatment for progressive familial intrahepatic cholestasis (PFIC) in people six months and older. Information for the public | Odevixibat for treating progressive familial intrahepatic cholestasis | Guidance | NICE

Now that the final step of the drug approval process is concluded, we know that the lives of children with PFIC and those who care for them can be transformed.

We would once again like to thank all our families who played a part in getting us here – those who took part in the trials of the new drug and those who took part in the appeals process following NICE’s original decision not to recommend the drug for the treatment of PFIC. It is a tremendous result and shows what can be achieved by working together.

We shall of course continue to work with our families and our partners on treatments to improve the lives of young people with liver disease.

Leave a Reply

© 2019 Children's Liver Disease Foundation. All Rights Reserved.